CA2757518A1 - Biomarkers for monitoring treatment of neuropsychiatric diseases - Google Patents
Biomarkers for monitoring treatment of neuropsychiatric diseases Download PDFInfo
- Publication number
- CA2757518A1 CA2757518A1 CA2757518A CA2757518A CA2757518A1 CA 2757518 A1 CA2757518 A1 CA 2757518A1 CA 2757518 A CA2757518 A CA 2757518A CA 2757518 A CA2757518 A CA 2757518A CA 2757518 A1 CA2757518 A1 CA 2757518A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- diagnostic
- magnetic stimulation
- transcranial magnetic
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 131
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 101
- 201000010099 disease Diseases 0.000 title claims abstract description 94
- 238000011282 treatment Methods 0.000 title claims abstract description 75
- 238000012544 monitoring process Methods 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 97
- 238000011491 transcranial magnetic stimulation Methods 0.000 claims abstract description 66
- 230000004044 response Effects 0.000 claims abstract description 27
- 239000012472 biological sample Substances 0.000 claims description 54
- 208000024714 major depressive disease Diseases 0.000 claims description 47
- 238000002560 therapeutic procedure Methods 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 32
- 230000002503 metabolic effect Effects 0.000 claims description 30
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 claims description 27
- 230000002757 inflammatory effect Effects 0.000 claims description 20
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 12
- 230000000508 neurotrophic effect Effects 0.000 claims description 11
- 210000002381 plasma Anatomy 0.000 claims description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
- 210000002442 prefrontal cortex Anatomy 0.000 claims description 7
- 230000003542 behavioural effect Effects 0.000 claims description 6
- 238000009225 cognitive behavioral therapy Methods 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000002651 drug therapy Methods 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 238000001671 psychotherapy Methods 0.000 claims description 4
- 238000013548 repetitive transcranial magnetic stimulation Methods 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 19
- 239000000463 material Substances 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 description 21
- 206010061218 Inflammation Diseases 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000012491 analyte Substances 0.000 description 15
- 208000020401 Depressive disease Diseases 0.000 description 12
- 238000004422 calculation algorithm Methods 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 7
- 238000004590 computer program Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000003900 neurotrophic factor Substances 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 5
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000003946 Prolactin Human genes 0.000 description 4
- 108010057464 Prolactin Proteins 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 3
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000003810 Interleukin-18 Human genes 0.000 description 3
- 108090000171 Interleukin-18 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102100029268 Neurotrophin-3 Human genes 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- 102100024735 Resistin Human genes 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 3
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 108091061482 Glial cell line-derived neurotrophic factor family Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 101800000933 Non-structural protein 10 Proteins 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108010047909 Resistin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007620 mathematical function Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000001414 neuropoietic effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 102400000630 Acylation stimulating protein Human genes 0.000 description 1
- 101800000415 Acylation stimulating protein Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 102100026376 Artemin Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 description 1
- 101000686909 Homo sapiens Resistin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000043322 Reelin Human genes 0.000 description 1
- 108700038365 Reelin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000011425 S100 Calcium Binding Protein beta Subunit Human genes 0.000 description 1
- 108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 238000001871 ion mobility spectroscopy Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940054157 lexapro Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102220300875 rs1554026816 Human genes 0.000 description 1
- 102220212642 rs747431847 Human genes 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- -1 serum amyloid P Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 102000015534 trkB Receptor Human genes 0.000 description 1
- 108010064880 trkB Receptor Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Primary Health Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16566209P | 2009-04-01 | 2009-04-01 | |
| US61/165,662 | 2009-04-01 | ||
| PCT/US2010/029720 WO2010115061A2 (en) | 2009-04-01 | 2010-04-01 | Biomarkers for monitoring treatment of neuropsychiatric diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2757518A1 true CA2757518A1 (en) | 2010-10-07 |
Family
ID=42828950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2757518A Abandoned CA2757518A1 (en) | 2009-04-01 | 2010-04-01 | Biomarkers for monitoring treatment of neuropsychiatric diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100280760A1 (https=) |
| EP (1) | EP2414824B1 (https=) |
| JP (1) | JP5675771B2 (https=) |
| CN (1) | CN102483398A (https=) |
| CA (1) | CA2757518A1 (https=) |
| WO (1) | WO2010115061A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158374B1 (en) | 2006-09-05 | 2012-04-17 | Ridge Diagnostics, Inc. | Quantitative diagnostic methods using multiple parameters |
| US8440418B2 (en) * | 2008-11-18 | 2013-05-14 | Ridge Diagnostics, Inc. | Metabolic syndrome and HPA axis biomarkers for major depressive disorder |
| WO2010045490A2 (en) * | 2008-10-15 | 2010-04-22 | Ridge Diagnostics, Inc. | Human biomarker hypermapping for depressive disorders |
| JP2012523009A (ja) * | 2009-04-06 | 2012-09-27 | リッジ ダイアグノスティックス，インコーポレイテッド | 精神神経疾患の治療をモニタリングするためのバイオマーカー |
| EP2529222A4 (en) * | 2010-01-26 | 2013-10-09 | Ridge Diagnostics Inc | MULTIPLE BIOMARKER PANELS FOR STRATIFYING ILLNESS HEAVY GRADES AND MONITORING THE TREATMENT OF DEPRESSIONS |
| EP2649456A4 (en) * | 2010-12-06 | 2015-01-07 | Ridge Diagnostics Inc | BIOMARKERS FOR MONITORING THE TREATMENT OF NEUROPSYCHIATRIC ILLNESSES |
| CA3141754A1 (en) * | 2011-10-24 | 2013-05-02 | President And Fellows Of Harvard College | Enhancing diagnosis of disorder through artificial intelligence and mobile health technologies without compromising accuracy |
| US10874355B2 (en) | 2014-04-24 | 2020-12-29 | Cognoa, Inc. | Methods and apparatus to determine developmental progress with artificial intelligence and user input |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| EP3506927A4 (en) | 2016-08-03 | 2020-05-06 | University of South Florida | REELIN COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES |
| CN118609834A (zh) | 2016-11-14 | 2024-09-06 | 科格诺亚公司 | 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置 |
| CA3053245A1 (en) | 2017-02-09 | 2018-08-16 | Cognoa, Inc. | Platform and system for digital personalized medicine |
| CN109568795B (zh) * | 2018-11-23 | 2023-01-24 | 中国医学科学院生物医学工程研究所 | 基于脑电溯源和线性相关的脑深部磁刺激靶点定位方法 |
| CA3134521A1 (en) | 2019-03-22 | 2020-10-01 | Cognoa, Inc. | Personalized digital therapy methods and devices |
| KR102365373B1 (ko) * | 2019-07-19 | 2022-02-21 | 연세대학교 산학협력단 | 재활 운동에 대한 치료 반응 예측 방법 및 키트 |
| US12564342B2 (en) | 2019-09-06 | 2026-03-03 | Cognoa, Inc. | Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments |
| CN115867980A (zh) * | 2020-07-02 | 2023-03-28 | 派尔疗法美国股份有限公司 | 用于生成和施用数字治疗安慰剂和伪物的系统、方法和设备 |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123938A1 (en) * | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| US20040265825A1 (en) | 2001-01-19 | 2004-12-30 | Boris Tartakovsky | Methods and compositions for diagnosing and treating a subject having depression |
| US20040152107A1 (en) * | 2002-09-18 | 2004-08-05 | C. Anthony Altar | Gene signature of electroshock therapy and methods of use |
| US7490085B2 (en) * | 2002-12-18 | 2009-02-10 | Ge Medical Systems Global Technology Company, Llc | Computer-assisted data processing system and method incorporating automated learning |
| US7706871B2 (en) * | 2003-05-06 | 2010-04-27 | Nellcor Puritan Bennett Llc | System and method of prediction of response to neurological treatment using the electroencephalogram |
| US7418290B2 (en) * | 2003-05-06 | 2008-08-26 | Aspect Medical Systems, Inc. | System and method of assessment of the efficacy of treatment of neurological disorders using the electroencephalogram |
| US20050084880A1 (en) * | 2003-07-11 | 2005-04-21 | Ronald Duman | Systems and methods for diagnosing & treating psychological and behavioral conditions |
| JP2005312435A (ja) | 2004-03-29 | 2005-11-10 | Kazuhito Rokutan | うつ病の評価方法 |
| KR20050115436A (ko) | 2004-06-02 | 2005-12-07 | 김은아 | 우울증 치료에 사용되는 '반복적 경두개 자기장 법'에 의하여 발현이 변화되는 흰쥐 뇌의 해마 유전자군. |
| JP2007024822A (ja) * | 2005-07-21 | 2007-02-01 | Aska Pharmaceutical Co Ltd | 男性の更年期又はうつ病の鑑別方法 |
| AU2006303026A1 (en) * | 2005-10-18 | 2007-04-26 | Psynova Neurotech Limited | Methods and biomarkers for diagnosing and monitoring psychotic disorders such as schizophrenia |
| WO2007067819A2 (en) | 2005-12-09 | 2007-06-14 | Precision Human Biolaboratory | Optical molecular detection |
| AU2007215739B2 (en) * | 2006-02-17 | 2014-01-16 | Atsuo Sekiyama | Biological load indicator and method of measuring biological load |
| US20080015465A1 (en) * | 2006-06-15 | 2008-01-17 | Scuderi Gaetano J | Methods for diagnosing and treating pain in the spinal cord |
| US7651836B2 (en) * | 2006-08-04 | 2010-01-26 | Hospital Santiago Apóstol | Methods for diagnosis and prognostic of psychiatric diseases |
| US8158374B1 (en) * | 2006-09-05 | 2012-04-17 | Ridge Diagnostics, Inc. | Quantitative diagnostic methods using multiple parameters |
| US20080199866A1 (en) * | 2006-10-10 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Snp detection and other methods for characterizing and treating bipolar disorder and other ailments |
| US20080281531A1 (en) | 2007-03-15 | 2008-11-13 | Kazuhito Rokutan | Method for Diagnosing Depression |
| US20110245092A1 (en) * | 2008-03-04 | 2011-10-06 | John Bilello | Diagnosing and monitoring depression disorders based on multiple serum biomarker panels |
| WO2009114627A2 (en) * | 2008-03-12 | 2009-09-17 | Ridge Diagnostics, Inc. | Inflammatory biomarkers for monitoring depression disorders |
| JP2012523009A (ja) * | 2009-04-06 | 2012-09-27 | リッジ ダイアグノスティックス，インコーポレイテッド | 精神神経疾患の治療をモニタリングするためのバイオマーカー |
| EP2529222A4 (en) * | 2010-01-26 | 2013-10-09 | Ridge Diagnostics Inc | MULTIPLE BIOMARKER PANELS FOR STRATIFYING ILLNESS HEAVY GRADES AND MONITORING THE TREATMENT OF DEPRESSIONS |
| EP2649456A4 (en) * | 2010-12-06 | 2015-01-07 | Ridge Diagnostics Inc | BIOMARKERS FOR MONITORING THE TREATMENT OF NEUROPSYCHIATRIC ILLNESSES |
-
2010
- 2010-04-01 JP JP2012503731A patent/JP5675771B2/ja not_active Expired - Fee Related
- 2010-04-01 WO PCT/US2010/029720 patent/WO2010115061A2/en not_active Ceased
- 2010-04-01 EP EP10759446.7A patent/EP2414824B1/en not_active Not-in-force
- 2010-04-01 CA CA2757518A patent/CA2757518A1/en not_active Abandoned
- 2010-04-01 US US12/753,022 patent/US20100280760A1/en not_active Abandoned
- 2010-04-01 CN CN2010800223067A patent/CN102483398A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102483398A (zh) | 2012-05-30 |
| EP2414824B1 (en) | 2017-12-06 |
| EP2414824A4 (en) | 2012-09-05 |
| EP2414824A2 (en) | 2012-02-08 |
| JP5675771B2 (ja) | 2015-02-25 |
| US20100280760A1 (en) | 2010-11-04 |
| WO2010115061A9 (en) | 2011-01-20 |
| WO2010115061A2 (en) | 2010-10-07 |
| JP2012522995A (ja) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2414824B1 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| US20100280562A1 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| US20120178118A1 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| JP5663314B2 (ja) | 多数のバイオマーカーパネルに基づくうつ障害の診断およびモニタリング | |
| US20170131295A1 (en) | Multiple biomarker panels to stratify disease severity and monitor treatment of depression | |
| JP5744063B2 (ja) | うつ病の疾患重症度を層別化するためおよび処置をモニタリングするための複数のバイオマーカーパネル | |
| JP5540000B2 (ja) | うつ病性障害のヒトバイオマーカーハイパーマッピング | |
| JP5658571B2 (ja) | うつ障害をモニタリングするための炎症バイオマーカー | |
| Taga et al. | Current and emerging ALS biomarkers: utility and potential in clinical trials | |
| Ganesalingam et al. | The application of biomarkers in clinical trials for motor neuron disease | |
| US20170161441A1 (en) | Methods and materials for treating pain and depression | |
| HK1171807A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1171081A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1190789A (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1164379A (en) | Human biomarker hypermapping for depressive disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150330 |
|
| FZDE | Discontinued |
Effective date: 20181212 |